Начало・Списък с акции・Arvinas Inc

Arvinas Inc

Затворен

СекторЗдравеопазване

8.94 11.75

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

9.61

Ключови измерители
By Trading Economics
Приходи	9.8M -58M
Продажби	6.1M 16M
EPS	-0.9
Марж на печалбата	-369.231
Служители	246
EBITDA	9.6M -56M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+80.77% upside

Дивиденти
By Acuity
Следващи печалби	4.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-103M 520M
Предишно отваряне	-2.81
Предишно затваряне	8.94

Настроения в новините

By Acuity

43%

57%

160 / 340 Класиране в Healthcare

Arvinas Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.08.2026 г., 20:02 ч. UTC

Social Media

News

Arvinas Inc shares rose following strong Q2 results, with EPS of $2.58 and revenue of $249.7 million, surpassing analyst expectations. BTIG reiterated its Buy rating.

3.08.2026 г., 19:46 ч. UTC

News

Arvinas Inc. shares are lower today, continuing a downward trend since Friday. Barclays raised its price target from $18.00 to $20.00 while maintaining an "overweight" rating.

31.07.2026 г., 20:06 ч. UTC

Arvinas Inc shares are declining amid broader market trends and rising Treasury yields. The stock remains below its 20-day moving average.

29.07.2026 г., 16:36 ч. UTC

Arvinas shares are lower today, trading near the lower end of their one-month range amid rising oil prices and inflation concerns.

28.07.2026 г., 20:06 ч. UTC

Arvinas Inc's shares are lower today, reflecting broader market trends amid a significant decline in Asian indices, particularly the Nikkei 225.

24.07.2026 г., 19:26 ч. UTC

Arvinas Inc. shares are lower amid a broader market decline influenced by falling crude oil prices, now near the lower end of their one-month range.

22.07.2026 г., 20:06 ч. UTC

Arvinas Inc. shares are near unchanged amid routine trading and cautious market sentiment ahead of the Federal Reserve meeting.

21.07.2026 г., 20:06 ч. UTC

Arvinas Inc shares are higher during Tuesday's session, tracking gains in the Nasdaq 100 Index amid strong technology sector performance. No specific news was identified.

Сравнение с други в отрасъла

Ценова промяна

Arvinas Inc Прогноза

Ценова цел

By TipRanks

80.77% нагоре

12-месечна прогноза

Среден 14.57 USD 80.77%

Висок 20 USD

Нисък 6 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Arvinas Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

9 ratings

Купи

Задържане

Продай

Според 9 анализатори, дали борсови рейтинги на Arvinas Inc през последните 3 месеца.

Настроение

By Acuity

160 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.